MeiraGTx Holdings Past Earnings Performance

Past criteria checks 0/6

MeiraGTx Holdings's earnings have been declining at an average annual rate of -13.5%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 11% per year.

Key information

-13.5%

Earnings growth rate

1.0%

EPS growth rate

Biotechs Industry Growth	-14.6%
Revenue growth rate	11.0%
Return on equity	-60.9%
Net Margin	-651.2%
Last Earnings Update	31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How MeiraGTx Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:328 Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Mar 24	11	-74	48	116
31 Dec 23	14	-84	47	104
30 Sep 23	7	-132	49	92
30 Jun 23	6	-125	50	81
31 Mar 23	14	-129	48	85
31 Dec 22	16	-130	47	86
30 Sep 22	42	-112	48	77
30 Jun 22	44	-101	45	82
31 Mar 22	39	-87	45	73
31 Dec 21	38	-80	44	67
30 Sep 21	20	-80	40	59
30 Jun 21	19	-61	41	42
31 Mar 21	16	-66	42	43
31 Dec 20	16	-58	44	34
30 Sep 20	19	-53	47	26
30 Jun 20	17	-57	48	26
31 Mar 20	17	-52	50	20
31 Dec 19	13	-55	47	25
30 Sep 19	6	-70	41	38
30 Jun 19	3	-75	38	42
31 Mar 19	1	-86	42	40
31 Dec 18	0	-85	44	34
30 Sep 18	0	-73	38	29
30 Jun 18	0	-66	33	27
31 Mar 18	0	-42	18	24
31 Dec 17	0	-32	9	22

Quality Earnings: 328 is currently unprofitable.

Growing Profit Margin: 328 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 328 is unprofitable, and losses have increased over the past 5 years at a rate of 13.5% per year.

Accelerating Growth: Unable to compare 328's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 328 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.8%).

Return on Equity

High ROE: 328 has a negative Return on Equity (-60.87%), as it is currently unprofitable.

MeiraGTx Holdings Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.62 loss in 1Q 2023)

Full year 2023 earnings released: US$1.49 loss per share (vs US$2.87 loss in FY 2022)

Third quarter 2023 earnings released: US$0.74 loss per share (vs US$0.83 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.53 loss per share (vs US$0.76 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.62 loss per share (vs US$0.70 loss in 1Q 2022)

Full year 2022 earnings released: US$2.87 loss per share (vs US$1.80 loss in FY 2021)

Recent updates

First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.62 loss in 1Q 2023)

MeiraGTx Holdings plc, Annual General Meeting, Jun 06, 2024

MeiraGTx Holdings plc Appoints Dr. Debra Yu to Serve on Each of the Compensation Committee and Science and Technology Committee of the Board

Full year 2023 earnings released: US$1.49 loss per share (vs US$2.87 loss in FY 2022)

Forecast to breakeven in 2025

MeiraGTx Holdings plc has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released: US$0.74 loss per share (vs US$0.83 loss in 3Q 2022)

MeiraGTx Holdings plc announced that it has received $30 million in funding from Sanofi Foreign Participations B.V.

New major risk - Share price stability

MeiraGTx Holdings plc Announces an Oral Presentation and Eight Posters At the European Society of Gene and Cell Therapy 2023 Annual Congress

New major risk - Financial position

Second quarter 2023 earnings released: US$0.53 loss per share (vs US$0.76 loss in 2Q 2022)

MeiraGTx Holdings plc Announces Positive Clinical Data from the AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx Holdings plc to Present 12-Month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study

First quarter 2023 earnings released: US$0.62 loss per share (vs US$0.70 loss in 1Q 2022)

MeiraGTx Holdings plc announced that it expects to receive $61.525 million in funding from Perceptive Advisors LLC, 683 Capital Management, LLC, Prosight Management, LP, Adage Capital Management, L.P.

Full year 2022 earnings released: US$2.87 loss per share (vs US$1.80 loss in FY 2021)

MeiraGTx Holdings plc cAnnounces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Insufficient new directors

Third quarter 2022 earnings released: US$0.83 loss per share (vs US$0.59 loss in 3Q 2021)

MeiraGTx Holdings plc announced that it has received $24.999994 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Second quarter 2022 earnings released: US$0.76 loss per share (vs US$0.46 loss in 2Q 2021)

MeiraGTx Holdings plc announced that it expects to receive $100 million in funding from Perceptive Advisors LLC

MeiraGTx Holdings plc announced that it expects to receive $100 million in funding from Perceptive Advisors LLC

MeiraGTx Holdings plc Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients Treated with Botaretigene Sparoparvovec (AAV-RPGR) Compared to Untreated Randomized Control

First quarter 2022 earnings released: US$0.70 loss per share (vs US$0.54 loss in 1Q 2021)

MeiraGTx Holdings plc Presents Clinical Data on Botaretigene Sparoparvovec for Treatment of X-Linked Retinitis Pigmentosa at Association for Research in Vision and Ophthalmology 2022 Annual Meeting

MeiraGTx Holdings plc, Annual General Meeting, Jun 07, 2022

MeiraGTx Appoints Debra Yu to Board of Directors

Insufficient new directors

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Insufficient new directors

MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Third quarter 2021 earnings released: US$0.59 loss per share (vs US$0.17 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.69 loss in 2Q 2020)

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.54 loss per share (vs US$0.43 loss in 1Q 2020)

Full year 2020 earnings released: US$1.54 loss per share (vs US$1.65 loss in FY 2019)

Revenue misses expectations

MeiraGTx Announces AAV-CNGA3 Granted Fast Track Designation by U.S. FDA for Treatment of Achromatopsia

MeiraGTx Holdings plc to Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia

New 90-day low: €10.00

Meiragtx Holdings plc and Chardan Capital Markets, LLC Announce Termination of a Material Definitive Agreement

MeiraGTx Holdings plc Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment

New 90-day high: €12.30

Revenue beats expectations

Third quarter 2020 earnings released: US$0.17 loss per share

MeiraGTx Holdings plc Reports Clinical Development

MeiraGTx Announces Nine-Month Data from Phase 1/2 Trial of AAV-RPGR Demonstrating Significant and Sustained Vision Improvement in X-Linked Retinitis Pigmentosa (XLRP)

MeiraGTx Holdings plc Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa

MeiraGTx Holdings plc (NasdaqGS:MGTX) acquired Emrys Bio Inc. for $7.7 million.

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta